covid
Buscar en
Endocrinología y Nutrición
Toda la web
Inicio Endocrinología y Nutrición Acromegalia, hiperparatiroidismo primario y feocromocitoma
Journal Information
Vol. 53. Issue 6.
Pages 382-386 (June 2006)
Share
Share
Download PDF
More article options
Vol. 53. Issue 6.
Pages 382-386 (June 2006)
Notas clínicas
Full text access
Acromegalia, hiperparatiroidismo primario y feocromocitoma
Acromegaly, primary hyperparathyroidism and pheochromocytoma
Visits
8180
Arturo Lisbona Gila,
, Mercedes Robledob, Asís Fernández Riestrac, César Alonso Rodrígueza
a Servicio de Endocrinología y Nutrición. Hospital Central de la Defensa. Madrid. España
b Servicio de Genética de Tumores Endocrinos. Centro Nacional de Investigaciones Oncológicas. Madrid. España
c Servicio de Medicina Interna. Hospital Central de la Defensa. Madrid. España
This item has received
Article information

Se presenta el caso de una mujer que 5 años después de haber sido diagnosticada de feocromocitoma adrenal derecho e hiperparatiroidismo primario, desarrolló una acromegalia por adenoma hipofisario. Se descartó la existencia de carcinoma medular de tiroides y de mutación germinal en RET y en VHL. La determinación del gen MEN-1 también resultó negativa. Se dan en este caso la existencia de un tumor característico de la NEM-2 como el feocromocitoma, otro característico de la NEM-1 como el adenoma hipofisario secretor de GH e hiperparatiroidismo primario, que se da en ambas neoplasias endocrinas múltiples, pero sin mutaciones germinales en RET, VHL y MEN-1.

Palabras clave:
Feocromocitoma
Acromegalia
Hiperparatiroidismo primario
NEM-1
NEM-2

We present the case of a 56-year-old woman who, 5 years after receiving a diagnosis of unilateral adrenal pheochromocytoma and primary hyperparathyroidism, was diagnosed with acromegaly caused by a growth hormonesecreting pituitary adenoma. No germ-line mutations in RET, VHL and MEN-1 gene were detected. Medullar thyroid carcinoma was also ruled out. Therefore, the present case shows coexistence of a tumor characteristic of MEN 2 syndrome (pheochromocytoma) with a growth hormone-secreting pituitary tumor characteristic of MEN 1 syndrome and primary hyperparathyroidism, which can be observed in both multiple endocrine neoplasia syndromes, but without germline mutations in RET, VHL and MEN-1.

Key words:
Pheochromocytoma
Acromegaly
Primary hyperparathyroidism
MEN-1
MEN-2
Full text is only aviable in PDF
Bibliografía
[1.]
A. Calender.
Molecular genetics of neuroendocrine tumors.
Digestion, 62 (2000), pp. 3-38
[2.]
T.M. Shattuck, S. Välimäki, T. Obara, R.D. Gaz, O.H. Clark, D. Shoback, et al.
Somatic and germ-line mutations of the HRPT2 in sporadic parathyroid carcinoma.
N Engl J Med, 349 (2003), pp. 1722-1729
[3.]
J.R. Zeller, H.M. Kauffman, R.A. Komorowski, H.D. Itskovitz.
Bilateral pheochromocytoma and islet cell adenoma of the pancreas.
Arch Surg, 117 (1982), pp. 827-830
[4.]
J.A. Carney, V.L. Go, H. Gordon, R.C. Northcutt, A.G. Pearse, S.G. Sheps.
Familial pheochromocitoma and islet cell tumor of the pancreas.
Am J Med, 68 (1980), pp. 515-521
[5.]
R. Tateishi, A. Wada, S. Ishiguro, M. Ehara, H. Sakamoto, T. Miki, et al.
Coexistence of bilateral pheochromocytoma and pancreatic islet cell tumor: report of a case and review of the literature.
Cancer, 42 (1978), pp. 2928-2934
[6.]
G.L. Miller, J. Wynn.
Acromegaly, pheochromocytoma, toxic goiter, diabetes mellitus and endometriosis.
Arch Intern Med, 127 (1971), pp. 299-303
[7.]
R.J. Anderson, E.G. Lufkin, G.W. Sizemore, J.A. Carney, S.G. Sep, Y.E. Silling.
Acromegaly and pituitary adenoma with phaeochromocytoma variant of multiple endocrine neoplasia.
Clin Endocrinol (Oxf), 14 (1981), pp. 605-612
[8.]
J.H. Myers, J.J. Eversman.
Acromegaly, hyperparathyroidism and pheochromocitoma in the same patient. A multiple endocrine disorder.
Arch Intern Med, 141 (1981), pp. 1521-1522
[9.]
J. Baughan, C. De Gara, D. Morrish.
A rare association between acromegaly and pheochromocytoma.
Am J Surg, 182 (2001), pp. 185-187
[10.]
G.G. Sleilati, K.T. Kovacs, M. Honasoge.
Acromegaly and pheochromocytoma: report of a rare coexistence.
Endocr Pract, 8 (2002), pp. 54-60
[11.]
S.C. Chandrasekharappa, S.C. Guru, P. Manickam, S.E. Olufemi, F.S. Collins, M.R. Emmert-Buck, et al.
Positional cloning of the gen for multiple endocrine neoplasia type 1.
Science, 276 (1997), pp. 404-407
[12.]
S.C. Guru, P.K. Goldsmith, A.L. Burns, S.J. Marx, A.M. Spiegel, F.S. Collins, et al.
Menin, the product of the MEN1 gene, is a nuclear protein.
Proc Natl Acad Sci U S A, 68 (1998), pp. 820-823
[13.]
S.K. Agarwal, S.C. Guru, C. Heppner, M.R. Erdos, R.M. Collins, S.Y. Park, et al.
Menin interacts with the AP1 transcription factor JunD and represses JunD-activated transcription.
Cell, 96 (1999), pp. 143-152
[14.]
S.K. Agarwal, M.B. Kester, L.V. Debelenko, C. Heppner, M.R. Emmert-Buck, M.C. Skarulis, et al.
Germline mutations of the MEN1 gene in familial multiple endocrine neoplasia type 1 and related states.
Hum Mol Genet, 6 (1997), pp. 1169-1175
[15.]
J.H. Bassett, S.A. Forbes, A.A. Pannett, S.E. Lloyd, P.T. Christie, C. Wooding, et al.
Characterization of mutations in patients with multiple endocrine neoplasia type 1.
Am J Hum Genet, 62 (1998), pp. 232-244
[16.]
K. Oberg, B. Skogseid, B. Eriksson.
Multiple endocrine neoplasia type 1 (MEN-1). Clinical, biochemical and genetical investigations.
Acta Oncol, 28 (1989), pp. 383-387
[17.]
R. Rizzoli, J. Green III, S.J. Marx.
Primary hyperparathyroidism in familial multiple endocrine neoplasia type I. Long-term follow- up of serum calcium levels after parathyroidectomy.
Am J Med, 78 (1985), pp. 467-474
[18.]
S.J. Marx, S.K. Agarwal, M.B. Kester, C. Heppner, Y.S. Kim, M.C. Skarulis, et al.
Multiple endocrine neoplasia type 1: clinical and genetic features of the hereditary endocrine neoplasias.
Recent Prog Hom Res, 54 (1999), pp. 397-438
[19.]
L.M. Mulligan, D.J. Marsh, B.G. Robinson, I. Schuffenecker, J. Zedenius, C.J. Lips, et al.
Genotype-phenotype correlation in multiple endocrine neoplasia type 2: report of the International RET Mutatium Consortium.
J Intern Med, 238 (1995), pp. 343-346
[20.]
L.M. Mulligan, J.B.J. Kwok, C.S. Healey, M.J. Elsdon, C. Eng, E. Gardner, et al.
Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A.
Nature, 363 (1993), pp. 458-460
[21.]
H. Donis-Keller, S. Dou, D. Chi, K.M. Carlson, K. Toshima, T.C. Lairmore, et al.
Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC.
Hum Mol Genet, 2 (1993), pp. 851-856
[22.]
L.M. Mulligan, C. Eng, C.S. Healey, D. Clayton, J.B. Kwok, E. Gardner, et al.
Specific mutations of the RET proto-oncogene are related to disease phenotype in MEN 2A and FMTC.
Nat Genet, 6 (1994), pp. 70-74
[23.]
W.M. Alberts, J.O. McMeekin, J.M. George.
Mixed multiple endocrine neoplasia syndromes.
JAMA, 244 (1980), pp. 1236-1237
[24.]
S.E. Carty, A.K. Helm, J.A. Amico, M.R. Clarke, T.P. Foley, C.G. Watson, et al.
The variable penetrance and spectrum of manifestations of multiple endocrine neoplasia type 1.
Surgery, 124 (1998), pp. 1106-1113
[25.]
A.P. Dackiw, G.J. Cote, J.B. Fleming, P.N. Schultz, P. Stanford, R. Vassilopoulou-Sellin, et al.
Screening for MEN1 mutations in patients with atypical endocrine neoplasia.
Surgery, 126 (1999), pp. 1097-1103
[26.]
E. Sigl, A. Behmel, T. Henn, G. Wirnsberger, A. Weinshäusl, K. Kaserer, et al.
Cytogenetic and CGH studies of four neuroendocrine tumors and tumor-derived cell lines of a patient with multiple endocrine neoplasia type 1.
Int J Oncol, 15 (1999), pp. 41-51
[27.]
A. Cebrián, S. Ruiz-Llorente, A. Cascón, M. Pollán, J.J. Díez, A. Picó, et al.
Mutational and gross deletion study of the MEN1 gene and correlation with clinical features in Spanish patients.
J Med Genet, 40 (2003), pp. e72
Copyright © 2006. Sociedad Española de Endocrinología y Nutrición
Article options
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos